Document:

<PAGE>
                                                                    EXHIBIT 4.30

        AMENDMENT TO AGREEMENT BETWEEN ENACT PHARMA PLC AND CHIMAERON LTD
                              DATED 1ST APRIL 2000.

22nd February 2001

Following a change, the registered address of the "Company" shall now read 8
Centre One, Old Sarum Park, Lysander Way, Salisbury, SP4 6BU.

Signed for both Parties by:

/s/ illegible                                   /s/ M.A. Atkinson
-----------------------------                   ------------------------------
for and on behalf of                            for and on behalf of
ENACT PHARMA PLC                                CHIMAERON LTD<PAGE>
                                                                    EXHIBIT 4.31

       AMENDMENT TO AGREEMENT BETWEEN ENACT PHARMA PLC AND CHIMAERON LTD
                              DATED 1ST APRIL 2000.

1st December 2001

The paragraph referring to Consultant's Fees shall be amended to read "The fee
is at present L90,000 per annum exclusive of VAT, or such other rate as
may be agreed from time to time payable monthly in arrears by bank credit
transfer. This agreement shall be terminable by either party giving to the
other not less than six months' prior written notice."

Signed for both Parties by:

/s/ signature to come                           /s/ M.A. Atkinson
-----------------------------                   ------------------------------
for and on behalf of                            for and on behalf of
ENACT PHARMA PLC                                CHIMAERON LTD<PAGE>
                                                                    EXHIBIT 4.32

                              LETTER OF APPOINTMENT

21st February 2001

Michael Peagram
Bletchingdon Park
Bletchingdon
Oxfordshire
OX5 3DW

Dear Michael

              ENACT PHARMA PLC (THE "COMPANY") AND YOUR APPOINTMENT
                           TO THE BOARD AS A DIRECTOR

My colleagues and I are pleased to hear that you have accepted our invitation to
join the Company as Chairman of the Board.

DUTIES

The Company shall engage you and you shall serve the Company on the terms of
this agreement (the "APPOINTMENT"). The Appointment shall continue until
terminated by either party giving the other not less than 6 months' prior
written notice. You will be required to attend all Board meetings of the
Company.

You should bear in mind that the liabilities and obligations of directors of
listed companies are more onerous and more rigorously enforced than those
relating to private companies. In common with the rest of the board, you will be
required to comply with the terms of the Stock Exchange Model Code for
transactions by directors of listed companies and specifically with any insider
dealing rules adopted by the Company from time to time.

DIRECTOR'S FEES

The fee is currently L24,000 per annum and will be subject to PAYE and
other statutory deductions where appropriate.

EXPENSES

The Company will reimburse you for any expenses that you may incur properly and
reasonably in performing your duties.

<PAGE>
OTHER INTERESTS

Other than set out in Schedule 1 to this agreement or as agreed with the Board
you shall not without the prior written consent of the Board during the
continuance of this agreement be concerned, engaged or interested either
directly or indirectly in any capacity in any other trade, business or
employment which is in competition with the business of the Company in the Field
as may be agreed with the Board provided that (other than any shares held in the
Company) you shall be permitted to hold not more than 3% of any class of shares
or debentures or other securities (other than shares, debentures or other
securities of the Company) which are quoted or dealt on the London Stock
Exchange or the Alternative Investment Market or any other recognised investment
exchange (as defined in section 207 of the Financial Services Act 1986) or
enterprise investment scheme or similar fund.

SECRECY

You shall not, except as authorised or required by his duties or obliged by law,
reveal to any person or use for you own purposes or for any purposes other than
those of the Company any of the trade secrets, secret or confidential
operations, processes or dealings or any information concerning the
organisation, prospective business, business methods, systems or affairs,
finances, transactions or affairs of any company in the Company, or any similar
information in relation to any customer or supplier of the Company, which may
come to your knowledge during and as a result of your employment and shall keep
with complete secrecy all confidential information entrusted to you and shall
not use or attempt to use any such information in any manner which may injure or
cause loss either directly or indirectly to the Company or their respective
businesses or may be likely so to do. This restriction shall continue to apply
to information or knowledge which is ordered to be disclosed by a Court of
competent jurisdiction or otherwise required to be disclosed by law.

The Company looks forward to working with you in the future.

Yours sincerely

/s/ illegible
-----------------------------------

For and on behalf of Enact Pharma Plc
<PAGE>
                                   SCHEDULE 1
                                OUTSIDE INTERESTS

<TABLE>
<CAPTION>
CURRENT DIRECTORSHIPS                                  APPOINTED

<S>                                                    <C>
Yule Catto and Co plc                                  9.2.1998
Valentia Air Ltd                                       9.7.1998
CMS Chemical Holdings Limited                         14.7.1998
Czech, Moravian and Slovak Chemicals Ltd              14.7.1998
Rinvol Ltd                                            12.3.1999
CRC Group PLC                                         27.5.1999
Shoplan UK Limited                                    11.8.1999
Stramar Industries Ltd                                11.8.1999
Magdalen College School Oxford Limited                01.4.1999
Alpha Eximport Ltd                                   19.10.2000
MCS Asset Management Ltd                             29.11.20OO
</TABLE><PAGE>

                                                                EXHIBIT 10.36(a)

                         [CONFIDENTIAL PORTIONS OMITTED]

                                                             [WARNER BROS. LOGO]
                                                                    WARNER BROS.
                                                               CONSUMER PRODUCTS

March 7, 2002

BAM! ENTERTAINMENT
333 West Santa Clara Avenue
Suite 716
San Jose, CA  95113
Attn:  Ray Musci

         RE:      WARNER BROS. LICENSE AGREEMENT #12697-DEX (DEXTER'S
                  LABORATORY) AMENDMENT NO. 1

Gentlemen:

This letter when fully executed shall formally amend that certain License
Agreement made October 4, 2000, relative to certain rights owned and controlled
by our client, Warner Bros.

By our mutual execution hereof, it is agreed as follows:

1.       PARAGRAPH 1(a) LICENSED PROPERTY:: is hereby amended by adding the
         following:

         Action Hank for One Gameboy Advance game

         Monkey for one game platform set forth below.

2.       PARAGRAPH 1(b) LICENSED PRODUCTS: is hereby amended by adding the
         following:

          iii)  Playstation I
          iv)   Playstation II
          v)    Microsoft X-Box
          vi)   Nintendo GameCube
          vii)  PC CD-Rom to specifically excluding educational titles
          vii)  Palm/OS cartridge to specifically excluding online distribution

         It is understood and agreed that for Licensed Product (ii) (Gameboy
         Advance) as set forth in the agreement Licensee can develop five
         original SKU's with no more than two original titles launching per
         year. Furthermore Licensee may develop three original SKU's (not
         including ports) for the Licensed Products (iii-vi) and Licensee may
         develop four original SKU's for Licensed Product (vii).
<PAGE>
BAM! ENTERTAINMENT
3/7/02
Page 2

                                                             [WARNER BROS. LOGO]

3.       PARAGRAPH 1(d) MARKETING DATE: is hereby deleted and replaced with the
         following:

         For purposes of subdivision 15(a)(vii), the Marketing Date for Licensed
         Products (i-iii) and (vii and viii) shall be no later than December 31,
         2002. For Licensed Products (iv-vi) shall be no later than October 1,
         2003.

4.       PARAGRAPH 3 TERM: is hereby amended with the following:

         The term ("Term") of the Agreement shall terminate on September 1,
2005.

5.       PARAGRAPH 4(a) GUARANTEED CONSIDERATION: is hereby amended by adding
         the following:

         GUARANTEED CONSIDERATION: the additional sum of $[*] payable as
         follows:
<TABLE>
<CAPTION>
         DATE                                                                   AMOUNT
         ----                                                                   ------
<S>                                                                             <C>
         Upon execution of the Amendment                                        $[*]

         On or before August 1, 2002                                            $[*]

         On or before December 1, 2002                                          $[*]

         On or before June 1, 2003                                              $[*]
</TABLE>

6.       PARAGRAPH 4(b) ROYALTY PAYMENTS: royalty rate percentage is hereby
         amended with the following:

         For Licensed Product iii) [*] of Net Sales;

         For Licensed Product vii) and viii) [*] of Net Sales; and

         For Licensed Products iv) - vi) [*] of Net Sales for unit sales from 1
         to 500,000; [*] from 500,001 to 1,000,000; and [*] from 1,000,001 and
         beyond.

--------
* Confidential portion omitted and filed separately with the Commission.

<PAGE>
BAM! ENTERTAINMENT
3/7/02
Page 3

                                                             [WARNER BROS. LOGO]

In all other respects, other than as noted above, the subject License Agreement
and all of its terms and conditions shall continue to govern our relationship.

Please show your concurrence with the above by signing all copies and returning
same to Warner Bros. Consumer Products. Upon final execution, one copy will be
sent to you for your files.

This letter shall have no legal effect unless and until signed by all parties
noted below.

Sincerely,                                    AGREED AND ACCEPTED:

WARNER BROS. CONSUMER PRODUCTS,               BAM! ENTERTAINMENT
a Division of Time Warner
Entertainment Company, L.P.

By:   /s/  Gary R. Simon                      By: /s/  Raymond Musci
      ------------------------------------        --------------------
      Gary R. Simon
      Senior Vice President, Business
      and Legal Affairs

Date  3/7/02                                  Date  3/8/02
      --------------------------------------        --------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]